ALZpath

Diagnosis Made Simple

[ALZpath @AlZpath]

ALZpath and Siemens Healthineers have signed a licensing agreement to accelerate global access to blood-based Alzheimer’s disease diagnostic testing.

🔗Read the full press release: https://t.co/42MIvOfrKx

[ALZpath @AlZpath]

🧠 June is Alzheimer's & Brain Awareness Month.

This month, we recognize the individuals, families, caregivers and communities impacted by Alzheimer's disease, along with those dedicated to advancing awareness, research, diagnosis, and care.

#AlzheimersDisease #ENDALZ

[Progress, Potential, And Possibilities @ProgressPotent1]

🚨What if Alzheimer’s could be detected years - even decades - before symptoms begin? 🧠

That future is closer than most people realize. 🚀

On the latest episode of @ProgressPotent1 I sat down with Mike Banville, CEO of @AlZpath

After decades scaling global businesses, Mike is now focused on one of healthcare’s biggest challenges:

👉Making early, accessible Alzheimer’s detection a reality.

We explore:
• How ALZpath’s pTau217 antibody is enabling blood tests that may rival PET scans and spinal taps;
• Why earlier detection could reshape clinical trials, treatment timing, and patient outcomes;
• The bigger shift toward precision medicine and proactive brain health;

This isn’t just about diagnostics - it’s about changing when the fight against Alzheimer’s begins. ⚕️

#Alzheimers #BrainHealth #Biotech #EarlyDetection #PrecisionMedicine #HealthcareInnovation #Dementia #Neuroscience #Longevity @FINNPartners @FPIPR @SiemensHealth @Roche @RocheDiaUSA @BCILifeSciences @BeckmanDx

[Alzheimer's Drug Discovery Foundation @TheADDF]

@Roche received CE Mark approval for the Elecsys pTau217 blood test, developed with @EliLillyandCo & powered by ADDF-funded @AlZpath’s pTau217 antibody. The approval marks another important step toward broader access to scalable Alzheimer’s diagnostics. https://t.co/ZhgwXfEFfz

[ALZpath @AlZpath]

@adpdnet Excited to see the conference underway. Looking forward to a great week of science at #ADPD2026.

[ALZpath @AlZpath]

With @adpdnet 2026 underway in Copenhagen, research featuring ALZpath’s pTau217 antibody appears across 29 scientific presentations.

Highlights from this week’s program below.

🔗 Read more: https://t.co/gNAMaMUxPS

[ALZpath @AlZpath]

1 week until AD/PD™ 2026 🧠

The global Alzheimer’s disease and Parkinson’s disease community will gather in Copenhagen, March 17–21.

Attending and want to connect? Reach out to Jacob Hunter at [email protected] to schedule a meeting.

[ALZpath @AlZpath]

We’re attending AD/PD 2026! ALZpath is excited to join the AD/PD™ 2026 Conference, March 17–21, in Copenhagen, Denmark.

If you will be attending and would like to connect, please reach out to Jacob Hunter at [email protected] to schedule a meeting.

#ADPD2026

[ALZpath @AlZpath]

🧠The words we use around brain health matter.

ALZpath has joined the Initiative to Change the “D-Word,” committing to remove outdated, stigmatizing language around cognitive impairment.

🔗Learn more in the full press release: https://t.co/tSLNmNACCa

[ALZpath @AlZpath]

We’re pleased to participate in the Global BioInnovation Forum today during @jpmorgan #JPM2026.

Our CEO Michael Banville will join a session moderated by @Gil_Bashe on how blood-based diagnostics are reshaping Alzheimer’s detection.

🕝 2:30 PM PT
🔗 https://t.co/298dESJJy2

[Longevity Technology @LongevityTech]

Bold move aims to scale blood-based diagnostics globally as demand for earlier, more accessible Alzheimer’s disease detection accelerates

https://t.co/XeL43aIglA

#longevity #Alzheimers #AlzheimersTesting #BloodTest #EarlyDetection #Neurodegeneration #HealthTech #MedTech

[ALZpath @AlZpath]

Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions.

🔗See the full list of posters & presentations: https://t.co/Tux252pqwt

[ALZpath @AlZpath]

📢#CTAD2025 is just two weeks away!

As we gear up to connect with leaders advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today🔗Explore: https://t.co/XYFTHe0CGm

Attending? Let’s connect: [email protected]

[ALZpath @AlZpath]

How reliable are blood-based pTau217 tests compared to PET or CSF?

Studies show blood tests powered by the #pTau217 antibody perform comparably to CSF tests for detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.

🔗 https://t.co/Ixgq0QDA3c

[ALZpath @AlZpath]

ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection.

🔗Read more: https://t.co/Ff8cu4yGgp

[Xtalks Webinars @Xtalks]

Pharma & biotech innovation is accelerating in 2025, from needle-free anaphylaxis rescue to AI-boosted newborn screening and blood-based Alzheimer’s diagnostics. The top 15 most innovative pharma & biotech companies of 2025, taken from Fast Company’s list, are redefining discovery, delivery and patient impact.

📊 Explore our infographic to see who’s leading and why:

• ARS Pharma (@ars_pharma)
• Bristol Myers Squibb (@bmsnews)
• Eli Lilly (@EliLillyandCo)
• Aurion Biotech (@AurionBiotech)
• Iovance Biotherapeutics (@IovanceBio)
• Adaptimmune (@Adaptimmune)
• Verona Pharma (@VeronaPharma)
• Pfizer (@pfizer)
• ImmunityBio (@ImmunityBio)
• Zevra Therapeutics (@zevratx)
• ALZpath (@AlZpath)
• GeneDX (@GeneDx)
• 10x Genomics (@10xGenomics)
• Protagonist Therapeutics (@ProtagonistTx)
• Recursion (@RecursionPharma)

👉 Read more here: https://t.co/2ggVpzuR9C

#Pharma #Biotech #Innovation #DrugDiscovery #ClinicalTrials #RareDisease #Oncology #Respiratory #Alzheimers #Genomics

[ALZpath @AlZpath]

In a new article from @PMLiVEcom, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing #Alzheimers blood testing - sensitivity, accessibility, and education - powered by #biomarkers like #pTau217.

🔗Read now https://t.co/HacAvjb1tM

[ALZpath @AlZpath]

We’re headed to #CTAD2025 in San Diego!

ALZpath will join global leaders in Alzheimer's disease research & diagnostics to discuss advances in #pTau217 and blood-based biomarkers.

Attending? Let’s connect - Reach out at [email protected] to schedule a meeting.
@CTADconference

[ALZpath @AlZpath]

@AlamarBio is advancing Alzheimer’s disease research with the launch of the NULISAqpcr™ BD-pTau217 Assay, built on ALZpath’s pTau217 antibody.

This launch broadens access to brain-specific blood-based biomarkers and marks another step forward in bringing innovative tools to AD.

[AlamarBio @AlamarBio]

🚀Just Launched: NULISAqpcr™ BD-pTau217 Assay! A game-changer in Alzheimer’s research—our new blood-based assay delivers unmatched sensitivity and CNS specificity for detecting brain-derived pTau217.
Learn more: https://t.co/5qpco6oGhb
Read the release: https://t.co/ztoXeJIlhx

[ALZpath @AlZpath]

@US_FDA #diagnostics #AlzheimersDisease #FDA #Biomarker #pTau217 #ALZpath

[ALZpath @AlZpath]

The @US_FDA approved LEQEMBI® IQLIK™, a new at-home injectable that targets amyloid to help slow early #Alzheimers.

Weekly at-home care removes infusion visits and improves access. #EarlyDetection is key to ensuring patients can benefit most.

📖https://t.co/cv9WZoKk80